In the medical and dental field, the importance and need for the study of materials and drugs for use as bone grafts or regeneration in injured areas due to the presence of fractures, infections or tumors that cause extensive loss of bone tissue is observed. Bone is a specialized, vascularized and dynamic connective tissue that changes throughout the life of the organism. When injured, it has a unique ability to regenerate and repair without the presence of scars, but in some situations, due to the size of the defect, the bone tissue does not regenerate completely. Thus, due to its importance, there is a great development in therapeutic approaches for the treatment of bone defects through studies that include autografts, allografts and artificial materials used alone or in association with bone grafts. Pharmaceuticals composed of biomaterials and osteogenic active substances have been extensively studied because they provide potential for tissue regeneration and new strategies for the treatment of bone defects. Statins work as specific inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoAreductase). They represent efficient drugs in lowering cholesterol, as they reduce platelet aggregation and thrombus deposition; in addition, they promote angiogenesis, reduce the β-amyloid peptide related to Alzheimer’s disease and suppress the activation of T lymphocytes. Furthermore, these substances have been used in the treatment of hypercholesterolemia and coronary artery disease. By inhibiting HMG-CoAreductase, statins not only inhibit cholesterol synthesis, but also exhibit several other beneficial pleiotropic effects. Therefore, there has been increasing interest in researching the effects of statins, including Simvastatin, on bone and osteometabolic diseases. However, statins in high doses cause inflammation in bone defects and inhibit osteoblastic differentiation, negatively contributing to bone repair. Thus, different types of studies with different concentrations of statins have been studied to positively or negatively correlate this drug with bone regeneration. In this review we will address the positive, negative or neutral effects of statins in relation to bone defects providing a comprehensive understanding of their application. Finally, we will discuss a variety of statin-based drugs and the ideal dose through a theoretical basis with preclinical, clinical and laboratory work in order to promote the repair of bone defects.
References
[1]
Ogita, M., Miyauchi, K., Miyazaki, T., et al. (2014) Low High-Density Lipoprotein Cholesterol Is a Residual Risk Factor Associated with Long-Term Clinical Outcomes in Diabetic Patients with Stable Coronary Artery Disease Who Achieve Optimal Control of Low-Density Lipoprotein Cholesterol. Heart and Vessels, 29, 35-41. https://doi.org/10.1007/s00380-013-0330-5
[2]
Kopin, L. and Lowenstein, C.J. (2017) Dyslipidemia. Annals of Internal Medicine, 167, 81-96. https://doi.org/10.7326/AITC201712050
[3]
Cases, A. and Coll, E. (2005) Dyslipidemia and the Progression of Renal Disease in Chronic Renal Failure Patients. Kidney International, 68, 87-93. https://doi.org/10.1111/j.1523-1755.2005.09916.x
[4]
Ballard-Hernandez, J. and Sall, J. (2023) Dyslipidemia Update. The Nursing Clinics of North America, 58, 295-308. https://Doi.Org/10.1016/J.Cnur.2023.05.002
[5]
Wang, L., Li, Y., Liu, Y., Zhang, H., Qiao, T., Chu, L., Luo, T., Zhang, Z. and Dai, J. (2023) Association between Different Types of Plant-Based Diets and Dyslipidemia in Middle-Aged and Elderly Chinese Participants. Nutrients, 15, Article 230. https://doi.org/10.3390/nu15010230
[6]
Farnier, M., Chen, E., Johnson-Levonas, A.O., et al. (2014) Effects of Extended-Release Niacin/Laropiprant, Simvastatin, and the Combination on Correlations between Apolipoprotein B, LDL Cholesterol, and Non-HDL Cholesterol in Patients with Dyslipidemia. Vascular Health and Risk Management, 10, 279-290. https://doi.org/10.2147/VHRM.S58694
[7]
Yadav, R., Liu, Y., Kwok, S., Hama, S., et al. (2015) Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients. Journal of the American Heart Association, 4, e001508. https://doi.org/10.1161/JAHA.114.001508
[8]
Teramoto, T., Abe, K. and Taneyama, T. (2013) Safety and Efficacy of Long-Term Combination Therapy with Bezafibrate and Ezetimibe in Patients with Dyslipidemia in the Prospective, Observational J-COMPATIBLE Study. Cardiovascular Diabetology, 12, Article No. 163. https://doi.org/10.1186/1475-2840-12-163
[9]
Tenenbaum, A. and Fisman, E.Z. (2012) Fibrates Are an Essential Part of Modern Anti-Dyslipidemic Arsenal: Spotlight on Atherogenic Dyslipidemia and Residual Risk Reduction. Cardiovascular Diabetology, 11, Article No. 125. https://doi.org/10.1186/1475-2840-11-125
[10]
Handelsman, Y., Jellinger, P.S., Guerin, C.K., et al. (2020) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm. Endocrine Practice, 26, 1196-1224. https://doi.org/10.4158/CS-2020-0490
[11]
Jellinger, P.S., Handelsman, Y., Rosenblit, P.D., et al. (2017) American Association of Clinical Endocrinologist and American College of Endocrinology Guidelines for Management of Sylipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 23, 1-87. https://doi.org/10.4158/EP171764.APPGL
[12]
Scott, M., Grundy, M.D., Neil, J.S., et al. (2019) Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139, e1178-e1181. https://doi.org/10.1161/CIR.0000000000000699
[13]
Maron, D.J., Fazio, S. and Linton, M.F. (2000) Current Perspectives on Statins. Circulation, 101, 207-213. https://doi.org/10.1161/01.CIR.101.2.207
[14]
Istvan, E.S. and Deisenhofer, J. (2001) Structural Mechanism for Statin Inhibition of HMG-CoA Reductase. Science, 292, 1160-1164. https://doi.org/10.1126/science.1059344
[15]
Camelia, S. and Anca, S. (2001) Statins: Mechanism of Action and Effects. Journal of Cellular and Molecular Medicine, 5, 378-387. https://doi.org/10.1111/j.1582-4934.2001.tb00172.x
[16]
Hirota, T., Fujita, Y. and Ieiri, I. (2020) An Updated Review of Pharmacokinetic Drug Interactions and Pharmacogenetics of Statins. Expert Opinion on Drug Metabolism & Toxicology, 16, 809-822 https://doi.org/10.1080/17425255.2020.1801634
[17]
Mukai, Y., Shimokawa, H., Matoba, T., et al. (2003) Acute Vasodilator Effects of HMG-CoA Reductase Inhibitors: Involvement of PI3-Kinase/Akt Pathway and Kv Channels. Journal of Cardiovascular Pharmacology, 42, 118-123. https://doi.org/10.1097/00005344-200307000-00018
[18]
Shepherd, J. (1993) Mechanism of Action of Fibrates. Postgraduate Medical Journal, 69, S34-S41.
[19]
Goa, K.L., Barradell, L.B. and Plosker, G.L. (1996) Bezafibrate: An Update of Its Pharmacology and Use in the Management of Dyslipidaemia. Drugs, 52, 725-753. https://doi.org/10.2165/00003495-199652050-00008
[20]
Packard, C.J. (1998) Overview of Fenofibrate. European Heart Journal, 19, A62-A65.
[21]
Dreyer, C., Krey, G., Keller, H., et al. (1992) Control of the Peroxisomal β-Oxidation Pathway by a Novel Family of Nuclear Hormone Receptors. Cell, 68, 879-887. https://doi.org/10.1016/0092-8674(92)90031-7
[22]
Rigano, D., Sirignano, C. and Taglialatela-Scafati, O. (2017) The Potential of Natural Products for Targeting PPARα. Acta Pharmaceutica Sinica B, 7, 427-438. https://doi.org/10.1016/j.apsb.2017.05.005
[23]
Friedenstein, A.J., Chailakhjan, R.K. and Lalykina, K.S. (1970) The Development of Fibroblast Colonies in Monolayer Cultures of Guinea-Pig Bone Marrow and Spleen Cells. Cell Proliferation, 3, 393-403. https://doi.org/10.1111/j.1365-2184.1970.tb00347.x
[24]
Pittenger, M.F., Mackay, A.M., Beck, S.C., et al. (1999) Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science, 284, 143-147. https://doi.org/10.1126/science.284.5411.143
[25]
Shilo, B.-Z. and Sprinzak, D. (2017) The Lipid-Binding Side of Notch Ligands. The EMBO Journal, 36, 2182-2183. https://doi.org/10.15252/embj.201797621
[26]
Guo, Z. and Ohlstein, B. (2015) Stem Cell Regulation. Bidirectional Notch Signaling Regulates Drosophila Intestinal Stem Cell Multipotency. Science, 350, Article aab0988. https://doi.org/10.1126/science.aab0988
[27]
Tikhonova, A.N., Dolgalev, I., Hu, H., et al. (2019) The Bone Marrow Microenvironment at Single-Cell Resolution. Nature, 569, 222-228. https://doi.org/10.1038/s41586-019-1104-8
[28]
Shen, G., Ren, H., Shang, Q., et al. (2020) Foxf1 Knockdown Promotes BMSC Osteogenesis in Part by Activating the Wnt/β-Catenin Signalling Pathway and Prevents Ovariectomy-Induced Bone Loss. eBioMedicine, 52, Article 102626. https://doi.org/10.1016/j.ebiom.2020.102626
[29]
The Prospective Epidemiological Risk Factors Study Group, Bagger, Y.Z., TankÓ, L.B., Alexandersen, P., et al. (2006) Radiographic Measure of Aorta Calcification Is a Site-Specific Predictor of Bone Loss and Fracture Risk at the Hip. Journal of Internal Medicine, 259, 598-605. https://doi.org/10.1111/j.1365-2796.2006.01640.x
[30]
Yao, W., Cheng, Z., Busse, C., et al. (2008) Glucocorticoid Excess in Mice Results in Early Activation of Osteoclastogenesis and Adipogenesis and Prolonged Suppression of Osteogenesis: A Longitudinal Study of Gene Expression in Bone Tissue from Glucocorticoid-Treated Mice. Arthritis and Rheumatism, 58, 1674-1686. https://doi.org/10.1002/art.23454
[31]
Zhao, L.-J., Liu, Y.-J., Liu, P.-Y., et al. (2007) Relationship of Obesity with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 92, 1640-1646. https://doi.org/10.1210/jc.2006-0572
[32]
Parhami, F., Tintut, Y., Beamer, W.G., et al. (2001) Atherogenic High-Fat Diet Reduces Bone Mineralization in Mice. Journal of Bone and Mineral Research,16, 182-188. https://doi.org/10.1359/jbmr.2001.16.1.182
[33]
Pagnotti, G.M., Styner, M., Uzer, G., et al. (2019) Combating Osteoporosis and Obesity with Exercise: Leveraging Cell Mechanosensitivity. Nature Reviews Endocrinology, 15, 339-355. https://doi.org/10.1038/s41574-019-0170-1
[34]
Feldman, S., Capozza, R.F., Mortarino, P.A., et al. (2012) Site and Sex Effects on Tibia Structure in Distance Runners and Untrained People. Medicine & Science in Sports & Exercise, 44, 1580-1588. https://doi.org/10.1249/MSS.0b013e31824e10b6
[35]
Capozza, R.F., Rittweger, J., Reina, P.S., et al. (2013) PQCT-Assessed Relationships Between Diaphyseal Design and Cortical Bone Mass and Density in the Tibiae of Healthy Sedentary and Trained Men and Women. Journal of Musculoskeletal & Neuronal Interactions, 13, 195-205.
[36]
Kan, B., Zhao, Q., Wang, L., et al. (2021) Association between Lipid Biomarkers and Osteoporosis: A Cross-Sectional Study. BMC Musculoskeletal Disorders, 22, Article No. 759. https://doi.org/10.1186/s12891-021-04643-5
[37]
Cointry, G.R., Capozza, R.F., Feldman, S., et al. (2012) Estructura, Funciones Y Calidad ÓSeas. In: Ardila, E., Mautalen, C. and JimÉNez, C., Eds., Osteoporosis En IberoamÉRica, 2nd Edition, El Manual Moderno, Bogotá, 33-71.
[38]
OdÉN, A., McCloskey, E.V., Kanis, J.A., et al. (2015) Burden of High Fracture Probability Worldwide: Secular Increases 2010-2040. Osteoporosis International, 26, 2243-2248. https://doi.org/10.1007/s00198-015-3154-6
[39]
Camal Ruggieri, I.N., CÍCero, A.M., Issa, J.P.M., et al. (2021) Bone Fracture Healing: Perspectives according to Molecular Basis. Journal of Bone and Mineral Metabolism, 39, 311-331. https://doi.org/10.1007/s00774-020-01168-0
[40]
Mundy, G., Garrett, R., Harris, S., et al. (1999) Stimulation of Bone Formation in vitro and in Rodents by Statins. Science, 286, 1946-1949. https://doi.org/10.1126/science.286.5446.1946
[41]
Reid, I.R., Hague, W., Emberson, J., et al. (2001) Effect of Pravastatin on Frequency of Fracture in the LIPID Study: Secondary Analysis of a Randomised Controlled Trial. Long-Term Intervention with Pravastatin in Ischaemic Disease. The Lancet, 357, 509-512. https://doi.org/10.1016/S0140-6736(00)04042-3
[42]
Maeda, T., Kawane, T. and Horiuchi, N. (2003) Statins Augment Vascular Endothelial Growth Factor Expression in Osteoblastic Cells via Inhibition of Protein Prenylation. Endocrinology, 144, 681-692. https://doi.org/10.1210/en.2002-220682
[43]
Oxlund, H., Dalstra, M. and Andreassen, T.T. (2001) Statin Given Perorally to Adult Rats Increases Cancellous Bone Mass and Compressive Strength. Calcified Tissue International, 69, 299-304. https://doi.org/10.1007/s00223-001-2027-5
[44]
Oxlund, H. and Andreassen, T.T. (2004) Simvastatin Treatment Partially Prevents Ovariectomy-Induced Bone Loss While Increasing Cortical Bone Formation. Bone, 34, 609-618. https://doi.org/10.1016/j.bone.2003.12.014
[45]
Bone, H.G., Kiel, D.P., Lindsay, R.S., et al. (2007) Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial. The Journal of Clinical Endocrinology & Metabolism, 92, 4671-4677. https://doi.org/10.1210/jc.2006-1909
[46]
Nezasa, K., Higaki, K., Takeuchi, M., et al. (2003) Uptake of Rosuvastatin by Isolated Rat Hepatocytes: Comparison with Pravastatin. Xenobiotica, 33, 379-388. https://doi.org/10.1080/0049825031000066259
[47]
Hughes, A., Rogers, M.J., Idris, A.I., et al. (2007) A Comparison Between the Effects of Hydrophobic and Hydrophilic Statins on Osteoclast Function in vitro and Ovariectomy-Induced Bone Loss in vivo. Calcified Tissue International, 81, 403-413. https://doi.org/10.1007/s00223-007-9078-1
[48]
Coxon, F.P., Helfrich, M.H., Van’t Hof, R., et al. (2000) Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298. Journal of Bone and Mineral Research, 15, 1467-1476. https://doi.org/10.1359/jbmr.2000.15.8.1467
Chuengsamarn, S., Rattanamongkoulgul, S., Suwanwalaikorn, S., et al. (2010) Effects of Statins vs. Non-Statin Lipid-Lowering Therapy on Bone Formation and Bone Mineral Density Biomarkers in Patients with Hyperlipidemia. Bone, 46, 1011-1015. https://doi.org/10.1016/j.bone.2009.12.023
[51]
Chen, P.-Y., Sun, J.-S., Tsuang, Y.-H., et al. (2010) Simvastatin Promotes Osteoblast Viability and Differentiation via Ras/Smad/Erk/BMP-2 Signaling Pathway. Nutrition Research, 30, 191-199. https://doi.org/10.1016/j.nutres.2010.03.004
[52]
Monjo, M., Rubert, M., Ellingsen, J.E., et al. (2010) Rosuvastatin Promotes Osteoblast Differentiation and Regulates SLCO1A1 Transporter Gene Expression in MC3T3-E1 Cells. Cellular Physiology and Biochemistry, 26, 647-656. https://doi.org/10.1159/000322332
[53]
Tsubaki, M., Satou, T., Itoh, T., et al. (2012) Bisphosphonate-and Statin-Induced Enhancement of OPG Expression and Inhibition of CD9, M-CSF, and RANKL Expressions via Inhibition of the Ras/MEK/ERK Pathway and Activation of P38MAPK in Mouse Bone Marrow Stromal Cell Line ST2. Molecular and Cellular Endocrinology, 361, 219-231. https://doi.org/10.1016/j.mce.2012.05.002
[54]
Boyce, B.F. and Xing, L. (2007) Biology of RANK, RANKL, and Osteoprotegerin. Arthritis Research & Therapy, 9, Article No. S1. https://doi.org/10.1186/ar2165
[55]
Lazzerini, P.E., Capperucci, C., Spreafico, A., et al. (2013) Rosuvastatin Inhibits Spontaneous and IL-1β-Induced Interleukin-6 Production from Human Cultured Osteoblastic Cells. Joint Bone Spine, 80, 195-200. https://doi.org/10.1016/j.jbspin.2012.07.007
[56]
Li, X., Wu, F., Zhang, Y., et al. (2016) Discontinuation of Simvastatin Leads to a Rebound Phenomenon and Results in Immediate Peri-Implant Bone Loss. Clinical and Experimental Dental Research, 2, 65-72. https://doi.org/10.1002/cre2.23
[57]
Zhou, H., Xie, Y., Baloch, Z., et al. (2017) The Effect of Atorvastatin, 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor (HMG-CoA), on the Prevention of Osteoporosis in Ovariectomized Rabbits. Journal of Bone and Mineral Metabolism, 35, 245-254. https://doi.org/10.1007/s00774-016-0750-2
[58]
Kırzıoğlu, F.Y., TözÜM Bulut, M., Doğan, B., et al. (2017) Anti-Inflammatory Effect of Rosuvastatin Decreases Alveolar Bone Loss in Experimental Periodontitis. Journal of Oral Science, 59, 247-255. https://doi.org/10.2334/josnusd.16-0398
[59]
Pradeep, A.R., Garg, V., Kanoriya, D., et al. (2016) 1.2% Rosuvastatin Versus 1.2% Atorvastatin Gel Local Drug Delivery and Redelivery in Treatment of Intrabony Defects in Chronic Periodontitis: A Randomized Placebo-Controlled Clinical Trial. Journal of Periodontology, 87, 756-762. https://doi.org/10.1902/jop.2016.150706
[60]
Pradeep, A.R., Karvekar, S., Nagpal, K., et al. (2016) Rosuvastatin 1.2 Mg in situ Gel Combined with 1:1 Mixture of Autologous Platelet-Rich Fibrin and Porous Hydroxyapatite Bone Graft in Surgical Treatment of Mandibular Class II Furcation Defects: A Randomized Clinical Control Trial. Journal of Periodontology, 87, 5-13. https://doi.org/10.1902/jop.2015.150131
[61]
Feng, X., Wang, C., Gu, Z., et al. (2019) Rosuvastatin Regulates Odontoblast Differentiation by Suppressing NF-κB Activation in an Inflammatory Environment. Cellular Reprogramming, 21, 18-25. https://doi.org/10.1089/cell.2018.0031
[62]
Leutner, M., Matzhold, C., Bellach, L., et al. (2019) Diagnosis of Osteoporosis in Statin-Treated Patients Is Dose-Dependent. Annals of the Rheumatic Diseases, 78, 1706-1711. https://doi.org/10.1136/annrheumdis-2019-215714
[63]
Hong, W., Wei, Z., Qiu, Z., et al. (2020) Atorvastatin Promotes Bone Formation in Aged ApoE-/- Mice through the Sirt1-Runx2 Axis. Journal of Orthopaedic Surgery and Research, 15, Article No. 303. https://doi.org/10.1186/s13018-020-01841-0
[64]
CÍCero, A.M., Issa, J.P.M. and Feldman, S. (2017) Matrices De Tercera GeneraciÓN En La IngenierÍA De Tejidos ÓSeos. Actualizaciones en Osteologìa, 13, Article 157.
[65]
Akbari, V., Rezazadeh, M. and Ebrahimi, Z. (2020) Comparison the Effects of Chitosan and Hyaluronic Acid-Based Thermally Sensitive Hydrogels Containing Rosuvastatin on Human Osteoblast-Like MG-63 Cells. Research in Pharmaceutical Sciences,15, 97-106. https://doi.org/10.4103/1735-5362.278719
[66]
Özer, T., Aktaş, A., Avağ, C., et al. (2021) Evaluation of the Effects of Locally Applied Rosuvastatin on Bone Formation in a Three-Dimensional Reconstruction Rabbit Xenograft Model. Turkish Journal of Medical Sciences, 51, 3115-3125. https://doi.org/10.3906/sag-2011-109
[67]
Gautam, K., Kapoor, A., Mathur, S., et al. (2022) Comparative Evaluation of Autogenous Bone Graft and Autologous Platelet-Rich Fibrin with and without 1.2 Mg in situ Rosuvastatin Gel in the Surgical Treatment of Intrabony Defect in Chronic Periodontitis Patients. Contemporary Clinical Dentistry, 13, 69-77. https://doi.org/10.4103/ccd.ccd_740_20
[68]
Wang, Z., Li, Y., Zhou, F., et al. (2016) Effects of Statins on Bone Mineral Density and Fracture Risk: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine, 95, e3042. https://doi.org/10.1097/MD.0000000000003042
[69]
Bahrami-Hessari, B. and Jansson, L. (2022) Peri-Implant Marginal Bone Loss and Systemic Statin Use: A Retrospective Cohort Pilot Study. Clinical and Experimental Dental Research, 8, 20-27. https://doi.org/10.1002/cre2.509
[70]
Leutner, M., Butylina, M., Matzhold, C., et al. (2023) Simvastatin Therapy in Higher Dosages Deteriorates Bone Quality: Consistent Evidence from Population-Wide Patient Data and Interventional Mouse Studies. Biomedicine & Pharmacotherapy,158, Article 114089. https://doi.org/10.1016/j.biopha.2022.114089
[71]
Sharma, P., Singh, A. and Mallapragada, S. (2023) Sub-Gingival Delivery of Simvastatin and Rosuvastatin for Treatment of Chronic Periodontitis with Diabetes Mellitus: A Randomized Controlled Clinical-Radiographic Pilot Study. Journal of Oral Biology and Craniofacial Research, 13, 315-320. https://doi.org/10.1016/j.jobcr.2023.02.012
[72]
Deepanjali, M., Prasad, T.S. and Manodh, P. (2023) Efficacy of Simvastatin in Bone Regeneration after Surgical Removal of Mandibular Third Molars. Oral and Maxillofacial Surgery, 27, 427-432. https://doi.org/10.1007/s10006-022-01081-y
[73]
Still, K., Grabowski, P., Mackie, I., et al. (2008) The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation in vivo. Calcified Tissue International, 83, 285-292. https://doi.org/10.1007/s00223-008-9175-9
[74]
Syversen, U., Stunes, A.K., Gustafsson, B.I., et al. (2009) Different Skeletal Effects of the Peroxisome Proliferator Activated Receptor (PPAR)α Agonist Fenofibrate and the PPAγ Agonist Pioglitazone. BMC Endocrine Disorders, 9, Article No. 10. https://doi.org/10.1186/1472-6823-9-10
[75]
Zhong, X., Xiu, L., Wei, G., et al. (2011) Bezafibrate Prevents Palmitate-Induced Apoptosis in Osteoblastic MC3T3-E1 Cells through the NF-κB Signaling Pathway. International Journal of Molecular Medicine, 28, 535-542.
[76]
Zhong, X., Xiu, L.L., Wei, G.H., et al. (2011) Bezafibrate Enhances Proliferation and Differentiation of Osteoblastic MC3T3-E1 Cells via AMPK and ENOS Activation. Acta Pharmacologica Sinica, 32, 591-600. https://doi.org/10.1038/aps.2011.15
[77]
Stunes, A.K., Westbroek, I., Gustafsson, B.I., et al. (2011) The Peroxisome Proliferator-Activated Receptor (PPAR) Alpha Agonist Fenofibrate Maintains Bone Mass, While the PPAR Gamma Agonist Pioglitazone Exaggerates Bone Loss, in Ovariectomized Rats. BMC Endocrine Disorders, 11, Article No. 11. https://doi.org/10.1186/1472-6823-11-11
[78]
Samadfam, R., Awori, M., BÉNardeau, A., et al. (2012) Combination Treatment with Pioglitazone and Fenofibrate Attenuates Pioglitazone-Mediated Acceleration of Bone Loss in Ovariectomized Rats. Journal of Endocrinology, 212, 179-186. https://doi.org/10.1530/JOE-11-0356
[79]
Smith, S.Y., Samadfam, R., Chouinard, L., et al. (2015) Effects of Pioglitazone and Fenofibrate Co-Administration on Bone Biomechanics and Histomorphometry in Ovariectomized Rats. Journal of Bone and Mineral Metabolism, 33, 625-641. https://doi.org/10.1007/s00774-014-0632-4
[80]
Şipoş, R.S., Fechete, R., Chelcea, R.I., et al. (2015) Ovariectomized Rats’ Femur Treated with Fibrates and Statins. Assessment of Pore-Size Distribution by ¹H-NMR Relaxometry. Romanian Journal of Morphology and Embryology, 56, 743-752.
[81]
Mosti, M.P., Ericsson, M., Erben, R.G., et al. (2016) The PPARα Agonist Fenofibrate Improves the Musculoskeletal Effects of Exercise in Ovariectomized Rats. Endocrinology, 157, 3924-3934.
[82]
Shi, T., Lu, K., Shen, S., et al. (2017) Fenofibrate Decreases the Bone Quality by Down Regulating Runx2 in High-Fat-Diet Induced Type 2 Diabetes Mellitus Mouse Model. Lipids in Health and Disease, 16, Article 201. https://doi.org/10.1210/en.2016-1114
[83]
Rovin, B.H., Barratt, J., Heerspink, H.J.L., et al. (2023)Efficacy and Safety of Sparsentan versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results from a Randomised, Active-Controlled, Phase 3 Trial. The Lancet, 402, 2077-2090. https://doi.org/10.1186/s12944-017-0592-5
[84]
Kim, Y.H., Jang, W.G., Oh, S.H., Kim, J.W., Lee, M.N., Song, J.H., et al. (2019) Fenofibrate Induces PPARα and BMP2 Expression to Stimulate Osteoblast Differentiation. Biochemical and Biophysical Research Communications, 520, 459-465. https://doi.org/10.1016/j.bbrc.2019.10.048
[85]
Thijssen, J.H. (2003) Overview on the Effects of Progestins on Bone. Maturitas, 46, 77-87. https://doi.org/10.1016/j.maturitas.2003.09.022
[86]
Alone, U.S. (2018) The Effects of Diuretics on Mineral and Bone Metabolism. Pediatric Endocrinology Reviews: PER, 15, 291-297.
[87]
Vestergaard, P. (2020) Drugs Causing Bone Loss. In: Stern, P.H., Ed., Bone Regulators and Osteoporosis Therapy, Vol. 262, Springer, Cham, 475-497. https://doi.org/10.1007/164_2019_340
